Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annu...( WAYNE N.J. and EMERYVILLE Calif. ...)

WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced more than 40 data presentations at the 2008 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the potential for Nexavar(R) (sorafenib) tablets in multiple tumor types as a single agent or in combination with other agents.

"Data at ASCO will expand upon and support the proven efficacy and tolerability of Nexavar in liver cancer and advanced kidney cancer and provide new insight into the potential of Nexavar in additional types of cancer," said Henry Fuchs, MD, executive vice president and chief medical officer of Onyx Pharmaceuticals. "Highlights include studies demonstrating that Nexavar extends life for Asian patients with liver cancer; provides an effective, well-tolerated option for elderly patients with advanced kidney cancer and may provide benefit and warrants further study in heavily pretreated patients with non-small cell lung cancer."

Nexavar data highlights include:

Hepatocellular Carcinoma

-- Randomized Phase III trial of sorafenib versus placebo in Asian

patients with advanced hepatocellular carcinoma

-- Ann Lii-Cheng, MD, PhD, department of internal medicine, National

Taiwan University Hospital, Taipei, Taiwan

-- Abstract #4509, oral presentation, Monday, June 02, 2008,

4:30 - 4:45 p.m., E-Hall D2

-- Efficacy and safety of sorafenib in patients with advanced

hepatocellular carcinoma and vascular invasion or extrahepatic spread:

a subanalysis from the SHARP trial

-- Morris Sherman, MD, PhD, associate professor of medic
'/>"/>